Drug Profile
Miricorilant - Corcept Therapeutics
Alternative Names: CORT-118335Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Corcept Therapeutics
- Class Cyclohexanes; Fluorinated hydrocarbons; Hepatoprotectants; Ketones; Pyrimidines; Small molecules
- Mechanism of Action Glucocorticoid receptor antagonists; Mineralocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alcoholism; Non-alcoholic steatohepatitis; Weight gain
- No development reported Metabolic disorders; Non-alcoholic fatty liver disease
Most Recent Events
- 10 Nov 2023 Efficacy and adverse events data from a phase I trial in Nonalcoholic steatohepatitis presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
- 26 Oct 2023 Corcept Therapeutics initiates the phase IIb MONARCH trial for Non-alcoholic steatohepatitis (PO) in US (NCT06108219)
- 17 Jul 2023 Corcept Therapeutics plans a phase IIb trial in Non-alcoholic-steatohepatitis in fourth quarter 2023